Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
SNRPC CRISPR/Cas9 KO Plasmid (h): sc-404002
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- SNRPC CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the SNRPC genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: SNRPC Antibody (4H12): sc-101549
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SNRPC CRISPR/Cas9 KO Plasmid (h) | sc-404002 | 20 µg | $397.00 |
Overview
SNRPC encodes a core Sm protein component of the U1 small nuclear ribonucleoprotein (snRNP), an essential subcomplex of the spliceosome that recognizes 5′ splice sites and promotes accurate pre-mRNA splicing. Through assembly of snRNP particles and stabilization of U1 snRNA–protein interactions, SNRPC supports spliceosome biogenesis, co-transcriptional RNA processing, and downstream gene expression programs. Disruption of spliceosomal components, including SNRPC, is linked to widespread splicing dysregulation that can affect cell-cycle control, DNA damage responses, and differentiation pathways. Altered spliceosome function has been associated with diverse human diseases, particularly cancers and inherited disorders driven by aberrant RNA processing.
SNRPC CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SNRPC gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the SNRPC together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the SNRPC open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish SNRPC protein expression.
This CRISPR knockout system enables efficient generation of SNRPC-deficient cell models for investigation of SNRPC signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting SNRPC exon(s) critical for SNRPC function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple SNRPC genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by SNRPC CRISPR/Cas9 KO Plasmid (h) and SNRPC CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the SNRPC locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by SNRPC HDR Plasmid (h) and SNRPC HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by SNRPC homology arms to support homology-directed repair at defined SNRPC target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.